CAFFEINE METABOLISM IN CYSTIC-FIBROSIS - ENHANCED XANTHINE-OXIDASE ACTIVITY

被引:21
作者
HAMELIN, BA [1 ]
XU, KY [1 ]
VALLE, F [1 ]
MANSEAU, L [1 ]
RICHER, M [1 ]
LEBEL, M [1 ]
机构
[1] UNIV LAVAL, ECOLE PHARM, PHARMACOCINET LAB, QUEBEC CITY G1K 7P4, PQ, CANADA
关键词
D O I
10.1038/clpt.1994.173
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study objective: To characterize the activities of the P450 mixed-function oxidase C gamma P1A2 as well as the cytosolic enzymes N-acetyltransferase and xanthine oxidase using caffeine as a probe in children with cystic fibrosis compared to age-matched healthy control subjects. Methods: After administration of caffeine (cola beverage) to 12 children with cystic fibrosis (age range, 5 to 11 years) and 12 healthy control subjects (age range, 5 to 12 years), urine was collected for 4 hours. Caffeine metabolites were determined by HPLC, and urinary caffeine metabolite ratios were computed to determine liver enzyme activities. In addition, a blood sample was used to detect cystic fibrosis mutant alleles by polymerase chain reaction. Results: The indexes for C gamma P1A2, N-acetyltransferase, and 8-hydroxylation were similar in both groups of subjects. In contrast, there was a significant difference in the frequency distribution of the xanthine oxidase activity between the tao groups. Nine of 12 patients with cystic fibrosis but only one of 12 healthy volunteers had xanthine oxidase activities above 0.42 (Kolmogorov-Smirnov two-sample test, p < 0.01). Conclusions: Differences in xanthine oxidase may have clinical implications with regard to interindividual variation in xenobiotic biotransformation and the exposure to lung tissue-damaging oxygen radicals. Hepatic enzyme activities appear to be selectively altered in patients with cystic fibrosis.
引用
收藏
页码:521 / 529
页数:9
相关论文
共 49 条
[31]   HUMAN N-ACETYLATION GENOTYPE DETERMINATION WITH URINARY CAFFEINE METABOLITES [J].
KILBANE, AJ ;
SILBART, LK ;
MANIS, M ;
BEITINS, IZ ;
WEBER, WW .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (04) :470-477
[32]   CYSTIC-FIBROSIS - ENHANCED THEOPHYLLINE METABOLISM MAY BE LINKED TO THE DISEASE [J].
KNOPPERT, DC ;
SPINO, M ;
BECK, R ;
THIESSEN, JJ ;
MACLEOD, SM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1988, 44 (03) :254-264
[33]   ALTERED PATTERNS OF DRUG-METABOLISM IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
LEE, BL ;
WONG, D ;
BENOWITZ, NL ;
SULLAM, PM .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (05) :529-535
[34]  
LELO A, 1989, J PHARMACOL EXP THER, V248, P315
[35]   ALTERED DISPOSITION OF FLEROXACIN IN PATIENTS WITH CYSTIC-FIBROSIS [J].
MIMEAULT, J ;
VALLEE, F ;
SEELMANN, R ;
SORGEL, F ;
RUEL, M ;
LEBEL, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1990, 47 (05) :618-628
[36]   N-ACETYLATOR VARIABILITY IN DOWNS-SYNDROME - CHARACTERIZATION WITH CAFFEINE [J].
MORRIS, ME ;
GRIENER, JC ;
MSALL, ME .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1989, 46 (03) :359-366
[37]   DISPOSITION OF DRUGS IN CYSTIC-FIBROSIS .5. IN-VIVO CYP2C9 ACTIVITY AS PROBED BY (S)-WARFARIN IS NOT ENHANCED IN CYSTIC-FIBROSIS [J].
OSULLIVAN, TA ;
WANG, JP ;
UNADKAT, JD ;
ALHABET, SMH ;
TRAGER, WF ;
SMITH, AL ;
MCNAMARA, S ;
AITKEN, ML .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :323-328
[38]  
PARKS DA, 1986, ACTA PHYSIOL SCAND, V126, P87
[39]  
PRANDOTA J, 1987, PEDIATR INFECT DIS J, V6, P1111
[40]   RACIAL AND GENDER DIFFERENCES IN N-ACETYLTRANSFERASE, XANTHINE-OXIDASE, AND CYP1A2 ACTIVITIES [J].
RELLING, MV ;
LIN, JS ;
AYERS, GD ;
EVANS, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (06) :643-658